Back to Search
Start Over
A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs.
- Source :
-
Frontiers in oncology [Front Oncol] 2022 Sep 26; Vol. 12, pp. 980694. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Breast cancer (BC) is the most common cancer in women worldwide. This highly heterogeneous disease is molecularly stratified into luminal A, luminal B, HER2, triple-negative/basal-like, and normal-like subtypes. An important aspect in BC progression is the activation of inflammatory processes. The activation of CD8+/Th1, NK, and M1 tumor associated macrophages (TAMs), leads to tumor destruction. In contrast, an anti-inflammatory response mediated by CD4+/Th2 and M2 TAMs will favor tumor progression. Inflammation also stimulates the production of inflammatory mediators like reactive oxygen species (ROS). In chronic inflammation, ROS activates oxidative stress and endothelial dysfunction. In cancer, ROS plays a dual role with anti-tumorigenic and pro-tumorigenic effects in cell signaling pathways that control proliferation, survival, apoptosis, and inflammation. MicroRNAs (miRNAs), which are known to be involved in BC progression and inflammation, can be regulated by ROS. At the same time, miRNAs regulate the expression of genes modulating oxidative stress. In this review, we will discuss the interplay between inflammation, ROS, and miRNAs as anticancer and tumor promoter molecules in BC. A clear understanding of the role of miRNAs in the regulation of ROS production and inflammation, may lead to new opportunities for therapy in BC.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Villarreal-García, Estupiñan-Jiménez, Vivas-Mejía, Gonzalez-Villasana, Vázquez-Guillén and Reséndez-Pérez.)
Details
- Language :
- English
- ISSN :
- 2234-943X
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 36226048
- Full Text :
- https://doi.org/10.3389/fonc.2022.980694